Elmiron lawsuits: more eye damage lawsuits keep getting filed

The interstitial cystitis drug Elmiron has been linked with a unique progressive eye disease known as pigmentary maculopathy. The disease can cause blurred vision, dark spots in the center of the field of vision, dim colors, problems with reading and trouble with eyesight in dim lighting.

The following Elmiron lawsuits have been filed recently:

Lawsuit filed on May 4

This woman’s complaint alleges that she developed maculopathy because of Elmiron. She started taking the drug in 2012 and her vision worsened over the next six years. The woman was diagnosed with permanent retinal injury in both of her eyes in March 2019.

Her lawsuit accuses Johnson & Johnson Pharmaceuticals and Janssen Pharmaceuticals of distributing, marketing and designing a “dangerously defective prescription drug” while “knowing significant risks that were never disclosed to the medical and healthcare community.”

The woman also accuses Janssen of withholding material adverse events and failing to “disclose the serious link between Elmiron use and significant visual damage, including pigmentary maculopathy.”

Elmiron’s label in the United States failed to warn about pigmentary maculopathy until it was updated in June. The drug’s Canadian label has warned about the condition since September 2019.

Lawsuit filed on June 8

This woman took Elmiron consistently from 2001 to 2018. The woman now suffers from severe injuries to the eye, including pigmentary maculopathy, loss of night vision, severe vision loss and changes in eye color pigment.

This woman is one of the six women in the initial Emory Eye Center study which discovered the new progressive eye disease. Her and the other five women all had the same symptoms and researchers discovered they all took Elmiron.

Some studies have found that up to 24% of Elmiron users end up with eye damage.

Lawsuit filed on March 26

This woman sued Teva Pharmaceuticals USA Inc. and Janssen Pharmaceuticals because she claims Elmiron caused her vision loss.

She started taking the drug in 2005 and started to suffer problems with her eyes in 2015. She saw numerous doctors about these problems from 2015 to 2019. She was diagnosed with permanent vision loss and retinal injury in 2019, and claims these conditions were caused by Elmiron.

Her complaint accuses the makers of Elmiron of failing to warn patients and medical providers about the vision problems linked with Elmiron. The complaint also alleges that Elmiron’s makers actively tried to hide the link to vision problems from the public.


About the author

Nadrich & Cohen, LLP

Nadrich & Cohen, LLP is a California personal injury law firm with offices in Los Angeles, San Francisco, Modesto, Fresno, Tracy and Palm Desert. The firm has been representing victims of dangerous drugs since 1990 and has recovered over $350,000,000 on behalf of clients in that time.